MethylGene logo

MethylGene

Harnessing Innovation to Develop Next-Generation Cancer Therapies

est. 1997

VS
Ventyx Biosciences logo

Ventyx Biosciences

242 employees · est. 2018 · San Diego, United States

MethylGene is the older company (1997 vs 2018).

Side-by-Side Comparison

MethylGene Ventyx Biosciences
Founded
1997 older 2018
Headquarters
Not tracked yet San Diego, United States
Employees
Not tracked yet 242
Industry
Biopharma, Biotechnology Biopharma, Biotechnology
Funding Stage
Series Unknown Post Ipo Equity
Total Funding
$71.83M $441.60M
Funding Rounds
4 4
Services
Not tracked yet Not tracked yet
Target Customers
Not tracked yet Not tracked yet
Taxonomy
Biopharmaceutical Company, Clinical Stage, Cancer Therapeutics, Kinase Inhibitors, HDAC Inhibitors, Oncology, Pharmaceutical Research, Clinical Trials, Drug Development, Neurodegenerative Diseases, Publicly Traded, Oncology Treatments, MethylGene Inc., Taiho Pharmaceutical Co. Ltd. Clinical Stage Programs, Inflammatory Diseases, Autoimmune Disorders, TYK2 Inhibitor, S1P1 Receptor Modulator, Ulcerative Colitis, NLRP3 Inflammasome, Phase 1 Clinical Trials, Phase 2 Clinical Trials, Drug Development, Fraud Alert, Cybercrime, FBI Warning, Pharmaceutical Industry
Website
methylgene.com ventyxbio.com
MethylGene logo

About MethylGene

MethylGene is a clinical stage biopharmaceutical company dedicated to the development and commercialization of innovative therapeutics primarily targeting cancer. Founded in 1997, it trades on the public market under the symbol TSX:MYG. The company's product portfolio includes MGCD265, an oral, mult...

Ventyx Biosciences logo

About Ventyx Biosciences

Ventyx Biosciences is a biotechnology company founded in 2018. It has a diverse portfolio of highly differentiated clinical and pre-clinical stage programs targeting high-value areas. The company's combined assets originate from three separate entities: Oppilan Pharma, focusing on S1P1R; Zomagen Bio...

We will tell you when either one moves

BounceWatch watches MethylGene and Ventyx Biosciences for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at MethylGene and Ventyx Biosciences — by email.

Frequently Asked Questions

MethylGene — Harnessing Innovation to Develop Next-Generation Cancer Therapies. Ventyx Biosciences. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
MethylGene has raised $71.83M while Ventyx Biosciences has raised $441.60M.
MethylGene and Ventyx Biosciences operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare MethylGene with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at MethylGene on 19 Jun 2024, and Ventyx Biosciences on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy